HER2 has been extensively studied in breast cancer, where gene amplification and overexpression of the protein is seen in approximately 20% cases and is associated with increased risk of recurrence and a poorer prognosis 3, 4, 5. This evidence concerns the gene ERBB2 and breast carcinoma.